MorphoSys AG — Investor Presentation 2012

Mar 26, 2012

Company Update

March 2012

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Maturing Pipeline Illustrates Successful Execution of Strategy

Total Phase 1 Phase 2

• 16 with seven different partners
• 4 proprietary, un-partnered programs
• Disease areas include cancer, inflammation, CNS, ophthalmology, musculoskeletal, and others

Strong Track Record of Technological Innovation

Slonomics: Multiple Opportunities Beyond Antibodies

76 Therapeutic Antibody Programs Ongoing, 20 in Clinical Trials

Program	Partner	Indication	Discovery	Pre-clinic	Phase 1	Phase 2
MOR103 (2 programs) -		Rheumatoid arthritis, Multiple sclerosis			New
CNTO888 (2 programs)	Janssen Biotech/J&J	Cancer, Idiopathic pulmonary fibrosis
CNTO1959	Janssen Biotech/J&J	Psoriasis				New
BHQ880	Novartis	Cancer
BYM338	Novartis	Musculoskeletal				New
NOV – 3	Novartis	not discl.
NOV – 4	Novartis	Ophthalmology				New
Gantenerumab	Roche	Alzheimer's Disease
MOR208	-	Cancer
MOR202	-	Cancer			New
BAY94-9343 (ADC) Bayer HealthCare		Cancer			New
BI – 1 Boehringer Ingelheim		not discl.
CNTO3157 Janssen Biotech/J&J		Asthma
CNTO – 5	Janssen Biotech/J&J	Inflammation
NOV – 5	Novartis	Inflammation
OMP-18R5	Oncomed	Cancer			New
OMP-59R5 Oncomed		Cancer
PFE – 1	Pfizer	Cancer
24 Partnered Programs	Various Partners	Various Indications
32 Programs, incl. 2 co-dev with Novartis	Various Partners	Various Indications			68 Partnered Programs 8 Proprietary Programs

New in 2011/2012

Page 7

Current Pipeline Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

The Drug

Ultra-high affinity HuCAL IgG1 targeting GM-CSF

Market

• Large commercial potential in inflammatory conditions including RA, MS, & others
• Revenues with approved biologics in RA in 2010 exceeded USD15bn

Intellectual Property

• Exclusive license to a US patent covering anti-GM-CSF antibodies for the treatment of chronic inflammatory conditions
• US patent on MOR103 composition of matter

Development

• European phase 1b/2a trial in RA fully recruited, data expected Q3 2012
• Ph1b safety study in MS patients initiated in Q4/11
• PK study for sc administration initiated in Q1/12

Phase 2 data for mavrilimumab, vs. GM-CSF receptor, provides clinical validation of the pathway in rheumatoid arthritis

Proportion of subjects achieving a change of 1.2 from baseline in DAS28-CRP

Source: ACR2011 Abstract: Mavrilimumab (an Anti-GM-CSFRα Monoclonal Antibody) in Subjects with Rheumatoid Arthritis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study

http://acr.confex.com/acr/2011/webprogram/Paper24567.html

GM-CSF is a Key Target in the Pathophysiology of Inflammatory Diseases

Adapted from: Hamilton JA, (2008) Nat Rev Immunol. 8:533-44

Trial	A Study of the safety and preliminary efficacy of MOR103, a human antibody to granulocyte macrophage colony-stimulating factor (GM-CSF)
Patients	Patients with active rheumatoid arthritis
Study Design	Randomized, double-blind, placebo-controlled, multi-center dose-escalation study (three groups with 0.3/1.0/1.5 mg/kg) of MOR103 on background of stable regimen of concomitant RA therapy (NSAIDs, steroids, non- biological DMARDs)
Primary Endpoint	Adverse event rate and safety profile
Secondary Endpoints	DAS28, ACR core set measures and EULAR28 response criteria, hematology, blood chemistry, Ig levels, cytokines, synovitis, bone edema
Study Details	 96 patients  Sites in Germany, The Netherlands, Bulgaria, Poland, Ukraine  Inclusion of MRI to detect an effect on inflammatory changes such as synovitis or bone edema  Results in Q3 2012

Trial	Phase Ib study to evaluate the safety and pharmacokinetics of MOR103, a human antibody to GM-CSF, in patients with multiple sclerosis (MS)
Patients	Patients with relapsing-remitting or secondary progressive MS (RRMS or SPMS)
Study Design	A randomized, double-blind, placebo-controlled study (three groups with 0.5/1.0/2.0 mg/kg; 6 doses) to evaluate the safety and pharmacokinetics of MOR103, a human antibody to GM-CSF, in patients with multiple sclerosis
Primary Endpoint	Incidence and severity of adverse events
Secondary Endpoints	 Pharmacokinetic profile  Potential immunogenicity
Study Details	 30 patients  Sites in Germany, Poland, UK  Results expected in 2013

MOR208 (XmAb5574) – A Novel High-Potential Anti-Cancer Antibody

The Drug

• Humanized, high affinity anti-CD19 antibody, exclusive license from Xencor
• Comprises a proprietary Xencor modification leading to rapid and sustained B-cell depletion

Market

High unmet medical need in NHL, CLL & ALL

Competitive Profile

• Expect convenient dosing schedule
• Straightforward manufacturing
• Potential for good safety profile
• Significantly increased ADCC compared to rituximab in vitro

Development

• Completion of phase 1 in CLL and reporting of interim data H2/12
• Initiation of additional trials in B cell malignancies in 2012

MOR208 (XmAb5574) Phase 1 Trial in the US

Trial	Safety and tolerability of MOR208 (XmAb5574) in Chronic Lymphocytic Leukemia
Patients	Patients with relapsed or refractory CLL/SLL
Study Design	 MOR208/XmAb5574 (humanized, Fc-engineered, anti-CD19 IgG1 antibody)  Open-label, multi-dose, single-arm, Phase 1, dose-escalation study
Primary Endpoint	To determine the dose limiting toxicities (time frame 28 days)
Study Details	 30 patients  Identification of the maximum tolerated dose (MTD) and/or recommended dose(s) (RD) for further study  Characterization of safety and tolerability, PK, PD and immunogenicity  Evaluation of preliminary antitumor activity of XmAb5574 in patients with relapsed or refractory CLL/SLL  Study sponsored by Xencor, Inc.

MOR202 – A Novel High-Potential Antibody for Multiple Myeloma

The Drug

High affinity HuCAL antibody targeting CD38

The Market

• High unmet medical need in MM, accounting for approximately 1% of all cancers.
• Median survival is approximately 3-5 years

Competitive Profile

• Use of targeted therapy in combination with standard regimens in myeloma can minimize adverse events while increasing efficacy
• MOR202 monotherapy shows a dose-dependent reduction of multiple myeloma graft induced bone lysis (pre-clinical studies)
• MOR202 plus bortezomib or lenalidomide synergistically inhibits bone lysis and substantially reduces M protein levels (pre-clinical studies)

Development

Study to last until January 2015, interim reporting planned

MOR202/BOR and MOR202/LEN combination therapy is superior to the respective mono therapies

Trial	A phase I/IIa, open-label, multicentre, dose-escalation study to evaluate the safety and preliminary efficacy of the human anti-CD38 antibody MOR202 as monotherapy and in combination with standard therapy in subjects with relapsed/refractory multiple myeloma
Patients	Patients relapsed/refractory multiple myeloma; failure of at least 2 prior therapies
Study Design	• MOR202 (anti-CD38 HuCAL IgG1 antibody) • Phase I dose escalation (iv administration of MOR202 for up to 2 cycles) • Phase IIa monotherapy extension (iv administration of MOR202 for up to 4 cycles) • Phase Ib MOR202 combined with bortezomib • Phase Ib MOR202 combined with lenalidomide
Primary Endpoint	• Determination of MTD and / or recommended dose (up to 20 weeks) • Safety & immunogenicity
Secondary Endpoints	• Pharmacokinetics of MOR202 • Overall response rate (standard response criteria, serum M protein levels)
Study Details	• Up to 82 patients • Study sites in Germany & Austria

AbD Serotec Segment Complements Therapeutic Business

Research Activities

• Catalogue of 15,000+ products
• Stable and recurring cash flows
• Customers comprise universities, government bodies, life science companies
• Website, eCommerce

HuCAL – Diagnostic Applications

• Custom antibody generation
• Using proprietary technologies to deliver superior Dx antibodies
• Future upside via royalties
• Collaborations with more than 20 diagnostics companies

FY2011: Income Statement

in € million	2011	2010	Change
Revenues	100.8	87.0	+16%
Cost of Goods Sold	7.0	7.3
Total Research and Development Expenses	57.5	46.9
Sales, General & Administrative Expenses	24.6	23.2
Total Operating Expenses	89.1	77.4	+15%
Other Operating Income	0.5	0.2
Profit from Operations	12.2	9.8	+24%
Finance Income	1.4	4.1
Other Expenses	2.1	0.8
Profit before Taxes	11.4	13.2	-14%
Income Tax Expenses	3.2	4.0
Net Profit	8.2	9.2	-11%
EPS (diluted)	0.36	0.40

Balance Sheet
EUR millions	Dec. 31, 2011	Dec. 31, 2010
Assets
Cash, Cash Equivalents & Marketable Securities	134.4	108.4
Other Current Assets	20.3	24.1
Total Non-Current Assets	73.7	77.3
Total Assets	228.4	209.8
Liabilities
Total Current Liabilities	23.8	21.4
Total Non-Current Liabilities	7.5	2.5
Total Shareholders' Equity	197.1	185.9
Total Liabilities	228.4	209.8

Shareholdings by Investor Type (12/2011)

in € million	2012	2011
Group Revenues	75 – 80	100.8
Investment into Proprietary R&D	20 – 25	36.7
Group EBIT	1 – 5	11.1

in € million	2012	2011
AbD Serotec Segment Revenues (at constant currency)	20 – 22	19.3
AbD Serotec EBIT Margin (at constant currency)	~ 6% – 8%	5%

Proprietary Clinical Programs to Advance Significantly in 2012

A Wealth of Clinical Data is Imminent

	H2 2011	H1 2012	H2 2012	H1 2013
NOV – 2 (Ophthalmology)
CNTO – 1 (Inflammation)				light colors: phase 1
CNTO888 (Cancer)				dark colors: phase 2
BYM338 (Musculoskeletal)				PoC in 2012
CNTO3157 (Asthma)
MOR208 (CLL)
BHQ880 (Cancer)
CNTO888 (IPF)
OMP18-R5 (Cancer)
OMP59-R5 (Cancer)
MOR103 (RA)
BYM338 (Musculoskeletal)
NOV – 3 (n.d.)
NOV – 3 (n.d.)
NOV – 4 (Ophthalmology)
PFE – 1 (Cancer)
CNTO1959 (Psoriasis)
BI – 1 (n.d.)
BHQ880 (Cancer)
NOV – 4 (Ophthalmology)
NOV – 4 (Ophthalmology)
NOV – 3 (n.d.)

Appendix

Novartis Alliance: Landmark Deal

Partnerships: Typical Terms per Program

Partnered Programs Phase 2 Clinical Development

Program	Partner	Disease	Target	Status
CNTO888	Janssen Biotech	Oncology	CCL2 (MCP-1)	Two trials ongoing, one trial completed
CNTO888	Janssen Biotech	Idiopathic pulmonary fibrosis	CCL2 (MCP-1)	Novel approach to IPF
CNTO1959	Janssen Biotech	Psoriasis	IL23p19	Phase 2 trial started in December 2011
n.d.	Novartis	n.d.	n.d.	Clinical proof of concept achieved
n.d.	Novartis	Ophthalmology	n.d.	Phase 2 trial started in January 2012
BHQ880	Novartis	Osteolytic bone disease	DKK-1	Early data show stimulation of bone formation
BYM338	Novartis	Musculoskeletal	n.d.	Two phase 2 trials ongoing
Gantenerumab	Roche	Alzheimer's disease	Amyloid-b	Only anti-Aβ antibody being developed in patients with prodromal AD

Partnered Programs Phase 1 Clinical Development

Program	Partner	Disease	Phase 1 Start
BAY94-9343	Bayer	Oncology	September 2011
n.d.	Boehringer Ingelheim	n.d.	December 2010
CNTO3157	Janssen Biotech	Asthma	June 2010
n.d.	Janssen Biotech	Inflammation / Autoimmune	December 2010
n.d.	Novartis	Inflammation	December 2010
OMP-18R5	Oncomed	Oncology	April 2011
OMP-59R5	Oncomed	Oncology	December 2010
n.d.	Pfizer	Oncology	December 2010

Carlumab (CNTO 888): CCL2 Specific Antibody in Oncology

A Study of the Safety and Efficacy of CNTO 888 in Combination With Standard of Care Chemotherapy in Patients With Solid Tumors

	Status	Phase 1 (completed)
	Study Design	Non-randomized, open-label safety study
	Study Start Date	May 2010
	Completion Date	n.d.
	Enrollment	53
	Primary Outcome Measures	The primary objective of the study is to evaluate the safety of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens (docetaxel; gemcitabine; Paclitaxel and carboplatin; or DOXIL®/ Caelyx® doxorubicin HCl liposome injection)
Secondary Outcome Measures		Pharmacokinetics [during study as specified in the protocol and at End of Study (1 year)] Pharmacodynamics [during study as specified in the protocol and at End of Study (1 year)]
	Treatment Period	Combination therapy will be continued until disease progression, unacceptable toxicity, the patient refuses further combination therapy, withdraws consent, or is treated for 1 year		Period

A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer

Status Phase 2 (completed)
	Study Design	Non-randomized, open-label safety/efficacy study
	Study Start Date September 2009
	Completion Date July 2011
	Enrollment	46
	Primary Outcome Measures	The primary objective of the study is to determine the composite response in patients with metastatic castrate-resistant prostate cancer (CRPC) who receive single-agent 15 mg/kg CNTO 888 every 2 weeks (Time Frame: 3-6 months)
	Secondary Outcome Measures	Objective response rate determined as complete response and partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines Progression Free Survival Overall Survival
	Treatment Period	15mg/kg intravenously every 2 weeks until disease progression

Carlumab (CNTO 888): CCL2 Specific Antibody in Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status	Phase 2 (active, not recruiting)
Study Design	Randomized, double-blinded safety/efficacy study
Study Start Date	December 2008
Completion Date	June 2012
Enrollment	129
Primary Outcome Measures	The primary objective is to determine the efficacy (as measured by pulmonary function) and safety of CNTO 888 in subjects with IPF.
Secondary Outcome Measures	To assess the effect of CNTO888 on measures of disease progression, patient reported outcomes, functional capacity and health-related quality of life, and to assess the pharmacokinetics/ pharmaco dynamics of CNTO888 in subjects with IPF.
Treatment Period	Patients will receive study agent until Week 48 and will continue to be followed through Week 72 for assessment of safety and any other effects after discontinuation of therapy. Patients will be in the study for about 74 weeks. Group 1: placebo Group 2: 1 g/kg CNTO888 every 4 weeks Group 3: 5mg/kg CNTO888 every 4 weeks Group 4: 15 mg/kg CNTO888 every 4 weeks

CNTO1959: HuCAL Antibody for the Treatment of Patients with Psoriasis

A Study to Evaluate CNTO 1959 in the Treatment of Patients
With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Status	Phase 2 (recruiting)
Study Design	Randomized, double-blind, placebo-controlled study
Study Start Date	October 2011
Completion Date	February 2014
Enrollment	280
Primary Outcome Measures	Physician's Global Assessment (PGA) score of cleared or minimal (Time Frame: Week 16); Overall assessment of induration, scaling, and erythema
Secondary Outcome Measures	Psoriasis Area and Severity Index (PASI) 75% or greater improvement from baseline (Time Frame: Week 16) The difference in the PGA score of cleared (0) or minimal (1) response rate between CNTO 1959 treatment groups and adalimumab treat ment group (Time Frame: Weeks 16 and 40) The change from baseline in Dermatology Life Quality Index (DLQI) (Time Frame: Week 16)
Treatment	 5 groups: CNTO 1959 (5 mg / 15 mg / 50 mg / 100 mg / 200 mg  Drug: Adalimumab  Drug: Placebo to CNTO 1959 (100 mg)

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single SC Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Status	Phase 1 (recruiting)
Study Design	Randomized, double-blind, placebo-controlled study
Study Start Date	August 2011
Completion Date	June 2013
Enrollment	32
Primary Outcome Measures	The number and type of adverse events  Change in clinical laboratory values Electrocardiogram  Changes or abnormalities in body systems Axillary temperature Pulse rate Blood pressure (Time Frame: Up to 24 weeks)
Secondary Outcome Measures	Blood levels of CNTO 1959 Antibodies to CNTO 1959 Psoriasis Area and Severity Index (PASI) Physician's Global Assessment (PGA)
Treatment	 Drug: CNTO 1959 (10mg, 30mg, 100mg, 300mg, subcutaneous use, ascending dosing for 24 weeks  Drug: Placebo

BHQ880: DKK-1 Specific Antibody in Multiple Myeloma Associated Osteolysis

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Status	Phase 1/2 (active, not recruiting)
Study Design	Randomized, double-blinded safety/efficacy study
Study Start Date	January 2009
Completion Date	April 2012
Enrollment	267
Primary Outcome Measures	Time to first SRE and change in bone markers for bone resorption and formation (Time Frame: 9 months minimum treatment with BHQ880 or placebo in combination with zoledronic acid and standard anti-myeloma therapy
Secondary Outcome Measures	 Characterize acute and chronic safety and tolerability of BHQ880  Characterize single-dose and repeated-dose pharmacokinetic profiles of BHQ880 Assess the potential immunogenicity of BHQ880  Characterize the binding kinetics of DKK1/BHQ880 complex (free&BHQ880 bound DKK1) in serum  Determine the pharmacodynamic effects of BHQ880 by measuring biochemical markers of bone formation, resorption, and metabolism in serum and urine
Treatment Period	 Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid Group 1: Various intravenous doses (low) of BHQ880 (up to 20 mg/kg) in combination with zoledronic acid on day 1 of a 28-day cycle. Goup 2: Various intravenous doses (medium) of BHQ880 (up to 20 mg/kg) in combination with zoledronic acid on day 1 of a 28-day cycle. Group 3: Various intravenous doses (high) of BHQ880 (up to 20 mg/kg) in combination with zoledronic acid on day 1 of a 28-day cycle. Group 4: Placebo in combination with zoledronic acid on day 1 of a 28-day cycle

BHQ880: DKK-1 Specific Antibody in Multiple Myeloma Associated Osteolysis

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Status	Phase 2 (recruiting)
Study Design	Non-randomized, open-label study
Study Start Date	May 2011
Completion Date	March 2013
Enrollment	40
Primary Outcome Measures	Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A (Time frame: at 6 months)
Secondary Outcome Measures	Safety and tolerability of BHQ880 in patients with smoldering multiple myeloma by assessing AEs, SAEs, clinical laboratory values (Time frame: From start of study until disease progression )  Characterize the PK profile of BHQ880 as a single agent administered monthly by assessing BHQ880 levels in plasma (Time frame: Throughout the study until disease progression) Evaluate the effect of BHQ880 on bone metabolism by assessing serum and urine bone biomarkers (Time frame: Throughout the study until disease progression) Evaluate the effect of BHQ880 on bone mineral density by DXA scan and QCT (Time frame: 6 months and 12 months)
Treatment Period	This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma BHQ880 will be administered every 28 days in previously untreated patients. Single arm

BHQ880: DKK-1 Specific Antibody in Multiple Myeloma Associated Osteolysis

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status	Phase 2 (recruiting)
Study Design	Randomized, double-blinded study
Study Start Date	May 2011
Completion Date	February 2016
Enrollment	144
Primary Outcome Measures	Effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone (Time Frame: 18-month median time to first SRE assumed for the placebo arm)
Secondary Outcome Measures	Safety and tolerability of BHQ880 in combination with bortezomib and dexamethasone  Characterize the PharmacoKinetics (PK) profiles of BHQ880 and bortezomib (Determine the pharmacokinetic parameters for BHQ880 and bortezomib. Evaluate the effect of BHQ880 on bone metabolism 1) Change in bone mineral density, measured by dual-emission X-ray absorptiometry (DXA), 2) Change in bone strength, measured by quantitative computed tomography (qCT),  Determine the anti-myeloma effect of BHQ880 compared to placebo when used in combination with bortezomib and dexamethasone 1) The overall response rate (partial response plus complete response); 2) Progression-free survival following initiation of BHQ880
Treatment Period	The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.

BYM338: HuCAL Antibody for the Unintentional Weight Loss in Cancer Patients

	Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis	Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Status	Phase 2 (recruiting)	Status	Phase 2 (recruiting)
Study Design	Randomized, double-blind, placebo-controlled study	Study Design	Randomized, double-blind, placebo-controlled study
Study Start Date	August 2011	Study Start Date	August 2011
Completion Date	December 2011	Completion Date	September 2012
Enrollment	12	Enrollment	50
Primary Outcome Measures	Assessment of the affect of BYM338 on thigh muscle volume by MRI (time frame: 8 weeks)	Primary Outcome Measures	Increase in thigh muscle volume as measured by MRI (Time Frame: 8 Weeks)
Secondary Outcome Measures	Assessment of the effect of BYM338 on muscle function by 'Timed Get Up and Go' test (Time frame: 8 weeks)	Secondary Outcome Measures	 6 minute walk test (Time frame: 8 weeks) Efficacy in treating unintentional weight loss (Time frame: 8 weeks) Obtain pharmacokinetic data in this population (Time frame: 8 weeks) Efficacy in improving total lean body mass (LBM) and total bone mineral content (Time frame: 8 weeks)  Improving physical activity and function (Time frame: 8 weeks)
Patients	Patients with sporadic Inclusion Body Myositis	Patients	Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas

Gantenerumab: Amyloid-ß Specific Antibody in Alzheimer's Disease

Management Team

Dr. Simon E. Moroney, CEO

• Co-founder, previously at ImmunoGen
• German Cross of the Order of Merit (2002), Bavarian State Medal for Outstanding Services to the Bavarian Economy (2009)

Jens Holstein, CFO

• Joined MorphoSys in 2011
• Formerly at Fresenius: Regional CFO for region EME of Fresenius Kabi AG; several financial and general management positions at Fresenius; and in consulting industry

Dr. Arndt Schottelius, CDO

• Joined MorphoSys in 2008
• Formerly Medical Director in Immunology at Genentech Inc.; Berlex Biosciences, USA; Schering, Germany; Charité University Hospital, Berlin

Dr. Marlies Sproll, CSO

• Joined MorphoSys in 2000, promoted to CSO in 2005
• Formerly at Boehringer Ingelheim in Vienna; Merck KGaA in Darmstadt

	Contact
Covering Analysts

Close Brother Seydler	Mr. Igor Kim
Commerzbank	Mr. Daniel Wendorff
Deutsche Bank	Mr. Gunnar Romer
DZ Bank	Dr. Elmar Kraus
Edison	Dr. Mick Cooper
Equinet Institutional Services	Edouard Aubéry
Helvea	Dr. Olav Zilian
Kempen & Co.	Mr. Sachin Soni / Mr. Mark Pospisilik
Landesbank Baden-Württemberg	Mr. Timo Kürschner
Nomura Code	Dr. Gary Waanders
WestLB AG	Dr. Cornelia Thomas / Mr. Oliver Kaemmerer

Upcoming Events & Conferences

 March 22, 2012	Kempen Healthcare/Life Sciences Conference Amsterdam, The Netherlands
 May 4, 2012	Q1 2012 Results
	Deutsche Bank Health Care Conference
May 7-9, 2012	Boston, USA
	German Swiss & Austrian Conference 2012
May 14-16, 2012	Frankfurt, Germany
 May 15-16, 2012	BioEquity, Frankfurt, Germany
	Jefferies 2012 Global Healthcare Conference
June 4-7, 2012	New York, USA

For more information please visit www.morphosys.com

Thank You

www.morphosys.com

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311 Fax +49 (0)89 / 899 27-5311 Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email investors@morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®, arYla®, CysDisplay®, RapMAT® and AutoCAL® are registered trademarks of MorphoSys AG. Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.